Tacforius Liên Minh Châu Âu - Tiếng Đan Mạch - EMA (European Medicines Agency)

tacforius

teva b.v. - tacrolimusmonohydrat - liver transplantation; kidney transplantation - immunosuppressiva - profylakse af transplantationsafstødning hos voksne nyre- eller levertransplantationsmodtagere. behandling af allograft afvisning resistente over for behandling med andre immunosuppressive lægemidler hos voksne patienter.

Tavlesse Liên Minh Châu Âu - Tiếng Đan Mạch - EMA (European Medicines Agency)

tavlesse

instituto grifols s.a. - fostamatinib dinatrium - trombocytopeni - andre systemiske hemostatics - tavlesse er indiceret til behandling af kronisk immun trombocytopeni (itp) hos voksne patienter, der er refraktære over for andre behandlinger.

Calquence Liên Minh Châu Âu - Tiếng Đan Mạch - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Copiktra Liên Minh Châu Âu - Tiếng Đan Mạch - EMA (European Medicines Agency)

copiktra

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Gavreto Liên Minh Châu Âu - Tiếng Đan Mạch - EMA (European Medicines Agency)

gavreto

roche registration gmbh  - pralsetinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.